MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    The Impact of Statin Therapy on Motor and Non-Motor Symptoms in Parkinson’s Disease: A Meta-Analysis

    V. Byroju, J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To assess the effects of statin therapy on motor and non-motor symptoms in Parkinson’s disease (PD) through a meta-analysis of randomized controlled trials. Background:…
  • 2025 International Congress

    Traditional Deep Brain Stimulation Programming versus Automated Image-Guided Algorithm in Patients with Parkinson’s Disease

    H. Maghzi, C. Kim, S. Worthge, C. Malatt, M. Tagliati (Los Angeles, USA)

    Objective: To compare traditional initial deep brain stimulation (DBS) programming with artificial intelligence (AI)-assisted automated image-guided DBS programming algorithm. Background: DBS programming is a complex,…
  • 2025 International Congress

    Cerebrospinal fluid measured α-synuclein is related to metabolite profile in the serum and CSF

    K. Paul, D. Jones, B. Ritz (Los Angeles, USA)

    Objective: Determine metabolites associated with cerebrospinal fluid (CSF) measured α-synuclein (α-syn) using untargeted metabolomics measured in the serum and CSF. Background: Several large studies have…
  • 2025 International Congress

    Case Report of a Brazilian Family With New VUS for PLAN

    M. Medeiros, M. Augustin (Porto Alegre, Brazil)

    Objective: The aim is to describe a Brazilian family with new VUS of PLA2G6 in two brothers with clinical symptoms of PLAN. Background: PLAN is…
  • 2025 International Congress

    The Effectiveness of Rivastigmine in Parkinson’s Disease: Impact on Motor Symptoms, Gait, Cognitive Function, and Falls – A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs

    V. Byroju, J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To evaluate the efficacy of rivastigmine in patients with Parkinson’s disease (PD) by assessing its impact on motor symptoms, cognitive function, gait, falls, and…
  • 2025 International Congress

    Detection of novel acoustic biomarkers among Parkinson’s disease patients via an explainable machine learning model

    K. Tsutsumi, P. Chang, S. Isfahani (San Diego, USA)

    Objective: Our aim was to develop and compare machine learning (ML) algorithms for identification of Parkinson’s disease (PD) patients via acoustic analysis of vowel articulation…
  • 2025 International Congress

    L-DOPA Induced Iron Accumulation in the Ventral Midbrain: The Roles of Sex and Iron Repletion

    R. Serpa, K. Palsa, E. Tufano, T. Helmuth, S. Mills-Huffnagle, M. Kant, J. Connor (Hershey, USA)

    Objective: This study aims to investigate the impact of L-3,4-dihydroxyphenylalanine (L-DOPA) on ventral midbrain (VMB) iron levels under iron deficiency (ID) and repletion (IR) conditions…
  • 2025 International Congress

    Cognitive Effects of Istradefylline in Parkinson’s Disease: A 26-Week Open-Label Pilot Study

    M. Barrett, R. Heo, N. Mukhopadhyay (Richmond, USA)

    Objective: The objective of this study was to collect preliminary evidence whether istradefylline may improve cognition in Parkinson’s disease (PD) patients with cognitive impairment. Background:…
  • 2025 International Congress

    Results from the PRIME-UK Randomised Controlled Trial

    K. Lloyd, E. Tenison, C. Mcdonald, S. Haworth, C. Glover, R. Harrison, D. Pendry-Brazier, M. Smith, F. Lithander, A. Cullen, K. Naylor, N. Giles, T. Gabriel, P. Kamnerdsupaphon, A. Nodehi, Y. Ben-Shlomo, EJ. Henderson (Bristol, United Kingdom)

    Objective: To evaluate whether PRIME-Parkinson care increases the ability of people with parkinsonism (PwP) to achieve their personal goals, has a positive impact on health…
  • 2025 International Congress

    Undescribed Variant of the THAP1 Gene Likely Pathogenic Associated with DYT6 – Case Report

    J. Sánchez León, T. Luise Denicol, C. Matté Dagostini, D. Dos Santos, C. Habekost, A. Hilbig, C. Mello Rieder (Porto Alegre, Brazil)

    Objective: To describe a case of dystonia DYT6 in which a variant of uncertain significance (VUS) in the THAP1 gene was found, which is likely…
  • « Previous Page
  • 1
  • …
  • 149
  • 150
  • 151
  • 152
  • 153
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Life expectancy with and without Parkinson’s disease in the general population
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley